



10 YEARS

OF HEARTMATE 3™ LVAD DATA

**UNMATCHED
EXPERIENCE
THAT'S
CONTINUOUSLY
GROWING**



38K+

PATIENTS IMPLANTED
TO DATE*



3.8K+

PATIENTS INCLUDED IN
CLINICAL TRIALS¹



60+

COUNTRIES IMPLANTING
SINCE 2014¹


MOMENTUM 3 PIVOTAL IDE TRIAL²:

**OUTSTANDING
SURVIVAL
OF NEARLY**



driven by a reduction in
hemocompatibility-related
adverse events**

ELEVATE REGISTRY³:




TWO-THIRDS of HeartMate 3™ LVAD patients experience
SYMPTOM RELIEF and an **IMPROVEMENT**
in **quality of life** and **functional capacity** through 5 years

ARIES-HM3 IDE TRIAL⁴:


The exclusion of aspirin for HeartMate 3 LVAD patients led to
REDUCTIONS OF:



NEARLY
40%
in GI bleeding
events



41%
in cost of care
for bleeding
events***



47%
in hospitalization
days due to bleeding
events***

INTERMACS[‡] 2024 ANNUAL REPORT⁵:

Real-world data shows
**OVERALL
SURVIVAL OF**

86%
at 1 year

60%
at 5 years

reaffirming what
was shown in the
MOMENTUM 3 trial

At 5 years, data also showed **HIGHER FREEDOM FROM:**



Stroke
(87%)



Device malfunction
(83%)



GI bleeding
(73%)

LEGACY OF IMPROVING HEART FAILURE OUTCOMES

10 YEARS

OF HEARTMATE 3™ LVAD DATA

HEARTMATE 3™ LVAD HAS RECEIVED A 1A RECOMMENDATION



1A RECOMMENDATION from the joint societies of AHA, ACC and HFSA is the strongest class of recommendation and the highest level of evidence.



This means that **benefits are supported by STRONG DATA** and far outweigh the risks.

WATCH ZULEYMA'S AND OTHERS' STORIES



to hear how the HeartMate 3™ LVAD has transformed patients' lives in countless ways.



COUNT ON THE HEARTMATE 3 LVAD —

the only LVAD with a decade of expert experience and trusted support.

TO LEARN MORE

about the HeartMate 3 LVAD, visit Cardiovascular.Abbott/HeartMate3

GI = gastrointestinal

IDE = investigational device exemption

LVAD = left ventricular assist device

*Based on clinical trial and device tracking data as of December 31, 2024.

**Stroke, device thrombosis and bleeding.

***Based on U.S. patients only.

1. Abbott. Data on File.
2. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. *JAMA*. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197
3. Schmitto JD, Shaw S, Garbade J, et al. Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry. *Eur Heart J*. 2024;45(8):613-625. doi:10.1093/eurheartj/ehad658
4. Mehra MR, Netuka I, Uriel N, et al. Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial. *JAMA*. 2023;330(22):2171-2181. doi:10.1001/jama.2023.23204
5. Meyer DM, Nayak A, Wood KL, et al. The Society of Thoracic Surgeons Intermacs 2024 annual report: focus on outcomes in younger patients. *Ann Thorac Surg*. 2025;119(1):34-58. doi:10.1016/j.athoracsur.2024.10.003

Abbott

6101 Stoneridge Dr., Pleasanton, CA 94588 USA, Tel: 1 925 847 8600
Cardiovascular.Abbott/HeartMate3

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

HeartMate 3™ LVAS Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

HeartMate 3™ LVAS Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3™ LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates a third-party trademark, which is property of its respective owner.

© 2025 Abbott. All Rights Reserved.

MAT-2502106 v1.0 | Item approved for U.S. use only.

